Whilst clinical trials of PD-1/PDL-1 inhibitors have been halted in MM following mixed results on safety and efficacy, IMiDs have also been shown to synergize with the widely-used anti-CD38 MM therapies, Daratumumab and Isatuximab. This evidence concerns the gene CD38 and Miyoshi myopathy.